Malaria elimination will be possible only with serious attempts to address asymptomatic
infection and chronic infection by both Plasmodium falciparum and Plasmodium vivax …

Plasmodium vivax malaria continues to cause a significant burden of disease in the Asia-
Pacific, the Horn of Africa, and the Americas. In addition to schizontocidal treatment, the 8 …

The only currently available drug that effectively removes malaria hypnozoites from the
human host is primaquine. The use of 8-aminoquinolines is hampered by haemolytic side …

A barrier to eliminating Plasmodium vivax malaria is inadequate treatment of infected
patients. 8-Aminoquinoline–based drugs clear the parasite; however, people with glucose-6 …

BACkGROunD Primaquine is currently the only medicine for treating relapses of
Plasmodium vivax and P. ovale malaria, due to its specific activity against malaria …

Objective We evaluated a battery of Glucose-6-Phosphate Dehydrogenase diagnostic point-
of-care tests (PoC) to assess the most suitable product in terms of performance and …

Background Glucose-6-phosphate dehydrogenase deficiency poses a significant
impediment to primaquine use for the elimination of liver stage infection with Plasmodium …

Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at risk of
severe haemolysis following the administration of 8-aminoquinoline compounds …

Background Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most
widespread enzyme defect that can result in red cell breakdown under oxidative stress when …

Glucose-6-phosphate dehydrogenase (G6PD) deficiency, a common genetic blood
condition, can result in kernicterus at birth, and later in life as severe hemolysis on exposure …